Long-term use of gonadotropin-releasing before IVF in women with endometriosis
Long-term use of gonadotropin-releasing before IVF in women with endometriosis
复制标题
DOI：
10.1097/gco.0b013e3281053a52
复制
发表时间：
2007-06-01
影响因子：
2.1
通讯作者：
Goker, Ege Nazan Tavmergen
中科院分区：
文献类型：
--
作者：
Tavmergen, Erol;Ulukus, Murat;Goker, Ege Nazan Tavmergen
目的审查讨论子宫内膜异位症和不孕症之间的关系，子宫内膜异位症对辅助生殖技术的影响，以及IVF前长期使用促性腺激素释放激素类似物在子宫内膜异位症妇女的好处。许多研究表明，子宫内膜异位症妇女即使在辅助生殖周期中，妊娠率和着床率也较低。众所周知，药物抑制子宫内膜异位症似乎并不保证子宫内膜异位症相关不孕症。据报道，IVF前长期使用促性腺激素释放激素类似物预处理可提高子宫内膜异位症不孕妇女的临床妊娠率，根据最近发表的数据，子宫内膜异位症不孕妇女可能受益于IVF前长期使用促性腺激素释放激素类似物预处理。
Purpose of review To discuss the relationship between endometriosis and infertility, the impact of endometriosis on assisted reproductive techniques and also the benefits of prolonged use of gonadotropin-releasing hormone analogue before IVF in women with endometriosis.Recent findings The available evidence suggests that endometriosis is strongly associated with infertility. Many studies indicate lower pregnancy and implantation rates even in assisted reproductive cycles in women with endometriosis. It is well known that medical suppression of endometriosis does not appear to be warranted for endometriosis-associated infertility. Prolonged pretreatment with gonadotropin-releasing hormone analogue before IVF has been reported to improve clinical pregnancy rates in infertile women with endometriosis.Summary Based on the recently published data, infertile women with endometriosis may benefit from long-term pretreatment of gonadotropin-releasing hormone analogue prior to IVF.